Skip to content

Taysha Gene Therapies, Inc. TSHA Return on invested capital

Return on invested capital at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-51%-21.2pp
Biogen logo
BiogenBIIB
7.8%-0.4pp
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
10%-34.0pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-475.4%+443pp
uniQure logo
uniQureQURE
-119%+424pp
Precigen logo
PrecigenPGEN
-204.2%-592pp

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.97B+351%
Enterprise value$1.76B+368%
P/S263.9×+203×

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Calculated from Taysha Gene Therapies, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Taysha Gene Therapies, Inc.'s return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Taysha Gene Therapies, Inc.'s return on invested capital?
Taysha Gene Therapies, Inc. (TSHA) reported return on invested capital of -6,605% in Q1 2026.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.